GlassScriptPhysician profile
Raza A Khan
NPI 1588623755
$22,412.44
in general payments reported to CMS, 2019-2025
55 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,858 · 2021: $1,498 · 2022: $243 · 2023: $1,301 · 2024: $715 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.91 |
| Education | $241.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,795.30 | 2019-2023 | Perjeta |
| Amgen INC. | $3,985.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,123.04 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $1,351.04 | 2019-2025 | Opdivo, Opdualag |
| Exelixis INC. | $756.72 | 2019-2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $353.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $256.20 | 2019-2025 | Jakafi |
| Jazz Pharmaceuticals INC. | $253.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $196.93 | 2019-2025 | |
| Celgene Corporation | $186.74 | 2019-2023 | Reblozyl |
| Pfizer INC. | $154.40 | 2019-2025 | |
| Abbvie INC. | $139.78 | 2019-2025 | |
| Legend Biotech USA INC. | $124.33 | 2025 | Carvykti |
| Lilly USA, LLC | $121.03 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Horizon Therapeutics Plc | $118.99 | 2022 |
Show all 52 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.